Skip to main content Back to Top
Advertisement

11/2/2020

Cabergoline Tablets

Products Affected - Description

    • Cabergoline tablet, Greenstone, 0.5 mg, bottle, 8 count, NDC 59762-1005-01
    • Cabergoline tablet, Ingenus Pharmaceuticals, 0.5 mg, bottle, 8 count, NDC 50762-0118-08
    • Cabergoline tablet, Par Pharmaceuticals, 0.5 mg, bottle, 8 count, NDC 49884-0673-14
    • Cabergoline tablet, Teva, 0.5 mg, bottle, 8 count, NDC 00093-5420-88

Reason for the Shortage

    • Greenstone did not provide a reason for the shortage.
    • Ingenus did not provide a reason for the shortage.
    • Par did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Greenstone has cabergoline 0.5 mg tablets available in limited supply.
    • Ingenus has cabergoline 0.5 mg tablets on back order and the company estimates a release date of early-November 2020.
    • Par has cabergoline 0.5 mg tablets on back order and the company cannot estimate a release date.
    • Teva has cabergoline 0.5 mg tablets on back order and the company estimates a release date of late-November 2020.

Updated

Created November 2, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.